AcelRx Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
AcelRx Pharmaceuticals, Inc.‘s stocks are currently a part of 44 hedge funds’ portfolios, which represents 42.33% of the total amount of its stocks outstanding. This makes up a total of 19.84M shares of AcelRx Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -33.96% or -10.20M shares fewer. As for the holding position changes, 20.45% (9) of current hedge fund investors increased the number of shares held, 20.45% (9) of current holders sold a part of the shares held, and 34.09% (15) closed the holdings completely. 5 hedge funds are new holders of AcelRx Pharmaceuticals, Inc. stock in Q1 2022, it is 11.36% of total holders.
Hedge funds holding AcelRx Pharmaceuticals (Q2 2017 – Q1 2022)
| Q2 2017 | 55 |
|---|---|
| Q3 2017 | 52 |
| Q4 2017 | 46 |
| Q1 2018 | 43 |
| Q2 2018 | 51 |
| Q3 2018 | 54 |
| Q4 2018 | 61 |
| Q1 2019 | 68 |
| Q2 2019 | 68 |
| Q3 2019 | 65 |
| Q4 2019 | 74 |
| Q1 2020 | 66 |
| Q2 2020 | 74 |
| Q3 2020 | 70 |
| Q4 2020 | 75 |
| Q1 2021 | 79 |
| Q2 2021 | 67 |
| Q3 2021 | 53 |
| Q4 2021 | 54 |
| Q1 2022 | 44 |
Hedge funds changes in AcelRx Pharmaceuticals positions (Q2 2017 – Q1 2022)
| Q2 2017 | 11 | 14 | 17 | 19 | -6 |
|---|---|---|---|---|---|
| Q3 2017 | 12 | 13 | 18 | 14 | -5 |
| Q4 2017 | 7 | 14 | 18 | 13 | -6 |
| Q1 2018 | 6 | 12 | 10 | 9 | 6 |
| Q2 2018 | 16 | 14 | 11 | 8 | 2 |
| Q3 2018 | 15 | 21 | 12 | 12 | -6 |
| Q4 2018 | 25 | 20 | 10 | 18 | -12 |
| Q1 2019 | 16 | 17 | 18 | 9 | 8 |
| Q2 2019 | 22 | 19 | 14 | 22 | -9 |
| Q3 2019 | 6 | 22 | 16 | 9 | 12 |
| Q4 2019 | 16 | 17 | 26 | 7 | 8 |
| Q1 2020 | 9 | 19 | 17 | 15 | 6 |
| Q2 2020 | 14 | 18 | 22 | 6 | 14 |
| Q3 2020 | 6 | 23 | 21 | 10 | 10 |
| Q4 2020 | 11 | 28 | 15 | 6 | 15 |
| Q1 2021 | 18 | 29 | 18 | 14 | 0 |
| Q2 2021 | 15 | 12 | 27 | 27 | -14 |
| Q3 2021 | 8 | 8 | 21 | 22 | -6 |
| Q4 2021 | 11 | 12 | 11 | 10 | 10 |
| Q1 2022 | 5 | 9 | 9 | 15 | 6 |
Hedge funds changes in AcelRx Pharmaceuticals stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 422,000 | 324,000 |
|---|---|---|
| Q3 2017 | 1,517,000 | 1,118,000 |
| Q4 2017 | 432,000 | 391,000 |
| Q1 2018 | 476,000 | 229,000 |
| Q2 2018 | 530,000 | 808,000 |
| Q3 2018 | 1,453,000 | 1,447,000 |
| Q4 2018 | 2,123,000 | 3,101,000 |
| Q1 2019 | 1,704,000 | 2,462,000 |
| Q2 2019 | 983,000 | 1,487,000 |
| Q3 2019 | 811,000 | 1,533,000 |
| Q4 2019 | 766,000 | 1,369,000 |
| Q1 2020 | 23,000 | 199,000 |
| Q2 2020 | 67,000 | 64,000 |
| Q3 2020 | 324,000 | 171,000 |
| Q4 2020 | 292,000 | 238,000 |
| Q1 2021 | 983,000 | 422,000 |
| Q2 2021 | 591,000 | 140,000 |
| Q3 2021 | 544,000 | 32,000 |
| Q4 2021 | 80,000 | 29,000 |
| Q1 2022 | 11,000 | 23,000 |